Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.

Cancer - 1 Aug 2020

Patrinely James R, Baker Laura X, Davis Elizabeth J, Song Haocan, Ye Fei, Johnson Douglas B

Abstract excerpt

BACKGROUND: Greater than one-half of patients with melanoma who are treated with antibodies blocking programmed cell death protein 1 receptor (anti-PD-1) experience disease progression. The objective of the current study was to identify prognostic factors and outcomes in patients with metastatic melanoma that progressed while they were receiving anti-PD-1 therapy. METHODS: The authors evaluated 383 consecutively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Immune Checkpoint Inhibitors

Share to Ipilimumab

Share to Nivolumab

Share to Programmed Cell Death 1 Receptor

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 32463489
DOI: 10.1002/cncr.32984
PMCID: PMC7695037

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.PMID 32463489Read ↗

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice.Semantic proximity Read ↗

BRAF and NRAS Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma.Semantic proximity Read ↗

Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.Semantic proximity Read ↗

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.Semantic proximity Read ↗

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.Semantic proximity Read ↗

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.Semantic proximity Read ↗

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.Semantic proximity Read ↗

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.Semantic proximity Read ↗

Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trialSemantic proximity Read ↗

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.Semantic proximity Read ↗

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.